Xi'an Oripharm Technology Co.,Ltd

“Dedicated to providing you with the best product solutions!”

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsWeight Loss SteroidsOrlistat Weight Loss Steroids Tetrahydrolipstatin CAS 96829-58-2 White Powder

Orlistat Weight Loss Steroids Tetrahydrolipstatin CAS 96829-58-2 White Powder

Orlistat Weight Loss Steroids Tetrahydrolipstatin CAS 96829-58-2 White Powder

Product Details:

Place of Origin: China
Brand Name: ORIPHARM
Certification: KOSHER/ISO9001/SGS
Model Number: XALY

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Packaging Details: Double food grade plastics inside; Environmental protection carton/barrel outside or Customized packages.
Delivery Time: 3-5 work days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: Negotiation
Contact Now
Detailed Product Description
Other Name: Tetrahydrolipstatin Formula: C29H53NO5
Formula Weight: 495.735 G·mol−1 CAS: 96829-58-2
Color: White Powder Assay: 99% Min

Orlistat Weight Loss Steroids Tetrahydrolipstatin for lossing weight CAS 96829-58-2

 

 

Product Name Orlistat
CAS No. 96829-58-2
Synonyms Tetrahydrolipstatin
Molecular Formula C29H53NO5
Molecular Weight 495.735 g·mol−1
Structure Orlistat Weight Loss Steroids Tetrahydrolipstatin CAS 96829-58-2 White Powder
Purity 99% min
Usage to weight loss
Character White powder
Grade Pharmaceutical Grade
Standard USP,CP
Delivery method EMS, DHL, TNT, FedEx

 

Description:

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2-3 kilograms (4.4-6.6 lb) more than those not taking the drug over the course of a year.Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). These decrease with time, however, and are the most frequently reported adverse effects of the drug.In the United States and the European Union, orlistat is available for sale without a prescription. Over-the-counter approval was controversial in the United States, with consumer advocacy group Public Citizen repeatedly opposing it on safety and efficacy grounds.Generic formulations of orlistat are available in some countries. In Australia it is listed as an S3 medication, which means it's available over the counter in pharmacies.

At times, such as in spring 2012, orlistat has come into short supply, with consequent price increases because of nonavailability of one of the drug's components.

Medical Fuctions:

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.

The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

 

Orlistat Weight Loss Steroids Tetrahydrolipstatin for lossing weight CAS 96829-58-2

 

COA:

Product Orlistat CAS No. 96829-58-2
Quantity 1KG Date Of Manu 2019-01-17
Test standard In-house quality standard Expiry date 2021-01-16
Items Specifications Results
Appearance White powder White powder
Assay ≥99.0% 99.49%
Loss on Drying ≤1.0% 0.4%
Conclusion: The product meets In-house specifications.
 
 
 





More information please contact us NOW!
 

Contact Details
Xi'an Oripharm Technology Co.,Ltd

Contact Person: forrest

Send your inquiry directly to us (0 / 3000)